Skip to main content

Table 6 Multivariate stepwise logistic regression analysis of variables associated with ischaemic heart disease and myocardial infarction

From: Interaction between smoking and functional polymorphism in the TGFB1 gene is associated with ischaemic heart disease and myocardial infarction in patients with rheumatoid arthritis: a cross-sectional study

Ischemic heart disease (model 1a) Myocardial infarction (model 2b)
Variable Regression coefficient OR (95% CI) Pvalue Variable Regression coefficient OR (95% CI) Pvalue
cSmoking+TGFB1+868TC 1.012 2.75 (1.59-4.75) 0.0003 cSmoking+TGFB1+868TC 0.948 2.58 (1.33-4.99) 0.0049
Age, per year 0.032 1.03 (1.01-1.06) 0.023 RF-positive 0.655 1.93 (0.93-3.99) 0.078
Male 0.744 2.10 (1.21-3.65) 0.0080 Male 0.972 2.64 (1.37-5.10) 0.0038
CRP ≥ 10 mg/L 1.030 2.80 (1.57-5.01) 0.0005 CRP ≥ 10 mg/L 0.810 2.25 (1.11-4.56) 0.025
Hypercholesterolemia 1.162 3.20 (1.69-6.04) 0.0003 Hypercholesterolemia 1.196 3.31 (1.58-6.91) 0.0014
dDiabetes 1.198 3.31 (1.36-8.06) 0.0083 Hypertension 1.009 2.74 (1.36-5.53) 0.0048
  1. aPatients with ischemic heart disease (IHD) versus those without IHD; bpatients with myocardial infarction (MI) versus all non-MI patients; cpatients who have ever smoked and carry the TGFB1+868 TC genotype in comparison with all remaining patients; dtype I or type II diabetes. Forward stepwise selection was used to determine the variables most strongly associated with IHD and MI. Variables excluded by the stepwise procedure for IHD were disease duration, hypertension, erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), body mass index (BMI), methotrexate treatment, steroid treatment, erosive disease, and nodular disease. Variables excluded by the stepwise procedure for MI were age, disease duration, ESR, anti-CCP, BMI, diabetes, methotrexate treatment, steroid treatment, erosive disease, and nodular disease. CI, confidence interval; CRP, C-reactive protein; OR, odds ratio; RF, rheumatoid factor; TGFB1, transforming growth factor-beta-1.